

## BIBLIOGRAPHY

- Abdel-Aziz, M.I., Ali, M.A.S., Hassan, A.K.M. & Elfaham, T.H. 2016. Warfarin-drug interactions: An emphasis on influence of polypharmacy and high doses of amoxicillin/clavulanate: Influence of polypharmacy and high doses of amoxicillin/clavulanate on warfarin. *The Journal of Clinical Pharmacology*. 56(1):39–46.
- Agno, W., Gallus, A.S., Wittkowsky, A., Crowther, M., Hylek, E.M. & Palareti, G. 2012. Oral Anticoagulant Therapy. *Chest*. 141(2):e44S–e88S.
- Agustini, T.T., Arifin, H. & Hanif, A.M. 2016. Perbandingan Dosis Warfarin terhadap Durasi Tercapainya Target INR pada Pasien CHF dengan Fibrilasi Atrial. 02(02):9.
- Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. & Palareti, G. 2008. Pharmacology and Management of the Vitamin K Antagonists. *Chest*. 133(6):160S–198S.
- Baillargeon, J., Holmes, H.M., Lin, Y.-L., Raji, M.A., Sharma, G. & Kuo, Y.-F. 2012. Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults. *The American Journal of Medicine*. 125(2):183–189.
- Battistella, M. 2005. Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors. *Archives of Internal Medicine*. 165(2):189.
- Bertram, V., Yeo, K., Anoopkumar-Dukie, S. & Bernaitis, N. 2019. Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range. *International Journal of Clinical Practice*. 73(11).
- Boccardo, P., Remuzzi, G. & Galbusera, M. 2004. Platelet Dysfunction in Renal Failure. *Seminars in Thrombosis and Hemostasis*. 30(5):579–589.
- Bungard, T.J., Yakiwchuk, E., Foisy, M. & Brocklebank, C. 2011. Drug Interactions Involving Warfarin: Practice Tool and Practical Management Tips. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 144(1):21–25.e9.
- Carroll, D.N. & Carroll, D.G. 2008. Interactions Between Warfarin and Three Commonly Prescribed Fluoroquinolones. *Annals of Pharmacotherapy*. 42(5):680–685.

- Cascorbi, I. 2012. Drug Interactions—Principles, Examples and Clinical Consequences. *Deutsches Ärzteblatt International*. 109(33–34):546–556.
- Chai-Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A. & Crowther, M. 2015. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *Journal of Thrombosis and Haemostasis*. 13(11):2012–2020.
- Chai-Adisaksopha, C., Hillis, C., Siegal, D.M., Movilla, R., Heddle, N., ... Crowther, M. 2016. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. *Thrombosis and Haemostasis*. 116(11):879–890.
- Chen, W.-C., Chen, Y.-H., Hsu, P.-I., Tsay, F.-W., Chan, H.-H., ... Lai, K.-H. 2014. *Gastrointestinal Hemorrhage in Warfarin Anticoagulated Patients: Incidence, Risk Factor, Management, and Outcome*. Vol. 2014. *BioMed Research International*. Hindawi.
- Choi, K.H., Kim, A.J., Son, I.J., Kim, K.-H., Kim, K.-B., ... Lee, E.B. 2010. Risk Factors of Drug Interaction between Warfarin and Nonsteroidal Anti-Inflammatory Drugs in Practical Setting. *Journal of Korean Medical Science*. 25(3):337.
- Clark, T.R. & Burns, S. 2011. Elevated International Normalized Ratio values associated with concomitant use of warfarin and ceftriaxone. *American Journal of Health-System Pharmacy*. 68(17):1603–1605.
- Clark, N.P., Witt, D.M., Delate, T., Trapp, M., Garcia, D., ... Crowther, M.A. 2008. Thromboembolic Consequences of Subtherapeutic Anticoagulation in Patients Stabilized on Warfarin Therapy: The Low INR Study. *Pharmacotherapy*. 28(8):960–967.
- Clark, N.P., Delate, T., Riggs, C.S., Witt, D.M., Hylek, E.M., ... Crowther, M.A. 2014. Warfarin Interactions With Antibiotics in the Ambulatory Care Setting. *JAMA Internal Medicine*. 174(3):409.
- Comoretto, R.I., Rea, F., Lucenteforte, E., Mugelli, A., Trifirò, G., ... Corrao, G. 2018. Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. *European Journal of Clinical Pharmacology*. 74(8):1061–1070.
- Copland, M., Walker, I.D. & Tait, R.C. 2001. Oral Anticoagulation and Hemorrhagic Complications in an Elderly Population With Atrial Fibrillation. *Archives of Internal Medicine*. 161(17):2125.

- Crowther, M., Garcia, D., Ageno, W., Wang, L., Witt, D., ... Kearon, C. 2010. Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study. *Thrombosis and Haemostasis*. 104(07):118–121.
- Dahal, K., Kunwar, S., Rijal, J., Schulman, P. & Lee, J. 2016. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease. *Chest*. 149(4):951–959.
- Dalal, J., Bhawe, A., Oommen, A., Vora, A., Saxena, A., ... Kaul, U. 2015. The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. *Indian Heart Journal*. 67(Suppl 2):S13–S34.
- D'Andrea, G., D'Ambrosio, R.L., Di Perna, P., Chetta, M., Santacroce, R., ... Margaglione, M. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. *Blood*. 105(2):645–649.
- Dechanont, S., Maphanta, S., Butthum, B. & Kongkaew, C. 2014. Hospital admissions/visits associated with drugdrug interactions: a systematic review and metaanalysis. *Pharmacoepidemiology and Drug Safety*. 9.
- Dentali, F. 2007. Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease: A Meta-analysis of Randomized Trials. *Archives of Internal Medicine*. 167(2):117.
- Douketis, J.D., Arneklev, K., Goldhaber, S.Z., Spandorfer, J., Halperin, F. & Horrow, J. 2006. Comparison of Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Ximelagatran or Warfarin: Assessment of Incidence, Case-Fatality Rate, Time Course and Sites of Bleeding, and Risk Factors for Bleeding. *Archives of Internal Medicine*. 166(8):853.
- Driver, B., Marks, D.C. & van der Wal, D.E. 2019. Not all (N)SAID and done: Effects of nonsteroidal anti-inflammatory drugs and paracetamol intake on platelets. *Research and Practice in Thrombosis and Haemostasis*. 4(1):36–45.
- Efird, L.M., Mishkin, D.S., Berlowitz, D.R., Ash, A.S., Hylek, E.M., ... Rose, A.J. 2014. Stratifying the Risks of Oral Anticoagulation in Patients With Liver Disease. *Circulation: Cardiovascular Quality and Outcomes*. 7(3):461–467.
- Eichinger, S. 2016. Reversing vitamin K antagonists: making the old new again. *Hematology: the American Society of Hematology Education Program*. 2016(1):605–611.

- Eikelboom, J.W., Connolly, S.J., Brueckmann, M., Granger, C.B., Kappetein, A.P., ... Van de Werf, F. 2013. Dabigatran versus Warfarin in Patients with Mechanical Heart Valves. *New England Journal of Medicine*. 369(13):1206–1214.
- Fahmi, A.M., Abdelsamad, O. & Elewa, H. 2016. Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. *SpringerPlus*. 5.
- Favaloro, E.J., McVicker, W., Lay, M., Ahuja, M., Zhang, Y., ... Hocker, N. 2016. Harmonizing the International Normalized Ratio (INR): Standardization of Methods and Use of Novel Strategies to Reduce Interlaboratory Variation and Bias. *American Journal of Clinical Pathology*. 145(2):191–202.
- Fischer, H.D., Juurlink, D.N., Mamdani, M.M., Kopp, A. & Laupacis, A. 2010. Hemorrhage During Warfarin Therapy Associated With Cotrimoxazole and Other Urinary Tract Anti-infective Agents: A Population-Based Study. *Archives of Internal Medicine*. 170(7).
- Fiske, W.D., Connell, J.M. & Benedek, I.H. 1995. Lack of Pharmacokinetic Interaction between Aspirin and Warfarin. *American Journal of Therapeutics*. 2(6):407–413.
- Foley, T.R., Waldo, S.W. & Armstrong, E.J. 2016. Antithrombotic therapy in peripheral artery disease. *Vascular Medicine*. 21(2):156–169.
- Gage, B.F., Yan, Y., Milligan, P.E., Waterman, A.D., Culverhouse, R., ... Radford, M.J. 2006. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). *American Heart Journal*. 151(3):713–719.
- Gallus, A.S., Baker, R.I., Chong, B.H. & Ockelford, P.A. 2000. Consensus guidelines for warfarin therapy. *The Medical Journal of Australia*. 172(12):600–605.
- Ghaswalla, P.K., Harpe, S.E., Tassone, D. & Slattum, P.W. 2012. Warfarin–Antibiotic Interactions in Older Adults of an Outpatient Anticoagulation Clinic. *The American Journal of Geriatric Pharmacotherapy*. 10(6):352–360.
- Gurwitz, J.H. 1992. Aging and the Anticoagulant Response to Warfarin Therapy. *Annals of Internal Medicine*. 116(11):901.
- Hansen, M.L., Sørensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunsø, J., ... Torp-Pedersen, C. 2010. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. *Archives of Internal Medicine*. 170(16).

- Herman, D., Locatelli, I., Grabnar, I., Peternel, P., Stegnar, M., ... Dolžan, V. 2006. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. *European Journal of Clinical Pharmacology*. 62(4):291–296.
- Higashi, M.K., Veenstra, D.L., Kondo, L.M., Wittkowsky, A.K., Srinouanprachanh, S.L., ... Rettie, A.E. 2002. Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy. *JAMA*. 287(13):1690–1698.
- Hogg, K. & Weitz, J.I. 2018. Blood Coagulation and Anticoagulant, Fibrinolytic, and Antiplatelet Drugs. In: L. Brunton, B. Knollman, & R. Hilal-Dandan, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. McGraw Hill Professional. pp. 585–603.
- Holbrook, A.M. 2005. Systematic Overview of Warfarin and Its Drug and Food Interactions. *Archives of Internal Medicine*. 165(10):1095.
- Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., ... Guyatt, G.H. 2012. Evidence-Based Management of Anticoagulant Therapy. *Chest*. 141(2):e152S-e184S.
- Holm, J., Lindh, J.D., Andersson, M.L. & Mannheimer, B. 2017. The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. *Journal of Thrombosis and Haemostasis*. 15(3):446–453.
- Holmes, M.V., Hunt, B.J. & Shearer, M.J. 2012. The role of dietary vitamin K in the management of oral vitamin K antagonists. *Blood Reviews*. 26(1):1–14.
- Horn, J.R. 2017. Important Drug Interactions & Their Mechanisms. In: *Basic and Clinical Pharmacology 14th Edition*. McGraw Hill Professional. pp. 1264.
- Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E. & Regan, S. 2007. Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation. *Circulation*. 115(21):2689–2696.
- Hylek, E.M., Chang, Y., Skates, S.J., Hughes, R.A. & Singer, D.E. 2000. Prospective Study of the Outcomes of Ambulatory Patients With Excessive Warfarin Anticoagulation. *Archives of Internal Medicine*. 160(11):1612–1617.
- Hylek, E.M., Go, A.S., Chang, Y., Jensvold, N.G., Henault, L.E., ... Singer, D.E. 2003. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. *New England Journal of Medicine*. 349(11):1019–1026.

- Israel, D.S., Stotka, J., Rock, W., Sintek, C.D., Kamada, A.K., ... Polk, R.E. 1996. Effect of Ciprofloxacin on the Pharmacokinetics and Pharmacodynamics of Warfarin. *Clinical Infectious Diseases*. 22(2):251–256.
- JCS Joint Working Group. 2014. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2013). *Circulation Journal*. 78(8):1997–2021.
- Joo Ng, H. & Crowther, M.A. 2006. Azathioprine and inhibition of the anticoagulant effect of warfarin: Evidence from a case report and a literature review. *The American Journal of Geriatric Pharmacotherapy*. 4(1):75–77.
- Kamali, F. & Wynne, H. 2010. Pharmacogenetics of Warfarin. *Annual Review of Medicine*. 61(1):63–75.
- Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., ... Kahn, S.R. 2012. Antithrombotic Therapy for VTE Disease. *Chest*. 141(2 Suppl):e419S-e494S.
- Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., ... Moores, L. 2016. Antithrombotic Therapy for VTE Disease. *Chest*. 149(2):315–352.
- Kementerian Kesehatan. 2019. *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/Menkes/813/2019 tentang Formularium Nasional*. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kent, A.P., Brueckmann, M., Fraessdorf, M., Connolly, S.J., Yusuf, S., ... Ezekowitz, M.D. 2018. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. *Journal of the American College of Cardiology*. 72(3):255–267.
- Kimmel, S.E. 2007. The Influence of Patient Adherence on Anticoagulation Control With Warfarin: Results From the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. *Archives of Internal Medicine*. 167(3):229.
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., ... Zeppenfeld, K. 2016. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *European Heart Journal*. 37(38):2893–2962.
- Knuuti, J., Wijns, W., Saraste, A., Capodanno, D., Barbato, E., ... Clapp, B. 2020. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European Heart Journal*. 41(3):407–477.
- Krajewski, K.C. 2010. Inability to Achieve a Therapeutic INR Value While on Concurrent Warfarin and Rifampin. *The Journal of Clinical Pharmacology*. 50(6):710–713.



- Kruse-Jarres, R. 2015. Acquired bleeding disorders in the elderly. *Hematology*. 2015(1):231–236.
- Kuruvilla, M. & Gurk-Turner, C. 2001. A review of warfarin dosing and monitoring. *Proceedings (Baylor University. Medical Center)*. 14(3):305–306.
- Lane, M.A., Zeringue, A. & McDonald, J.R. 2014. Serious Bleeding Events due to Warfarin and Antibiotic Co-prescription in a Cohort of Veterans. *The American Journal of Medicine*. 127(7):657-663.e2.
- Launiainen, T., Sajantila, A., Rasanen, I., Vuori, E. & Ojanperä, I. 2010. Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study. *European Journal of Clinical Pharmacology*. 66(1):97–103.
- Leavitt, A.D. & Minichiello, T. 2018. Disorders of Hemostasis, Thrombosis, & Antithrombotic Therapy. In: M.A. Papadakis, S.J. McPhee, & M.W. Rabow, eds. *CURRENT Medical Diagnosis and Treatment 2019*. McGraw Hill Professional. pp. 556–588.
- Lee, S., Ng, S., Oldenburg, J., Chong, P., Rost, S., ... Yeo, T. 2006. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. *Clinical Pharmacology & Therapeutics*. 79(3):197–205.
- Lemeshow, S., Jr, D.W.H., Klar, J. & Lwanga, S.K. 1990. *Adequacy of Sample Size in Health Studies*. Wiley.
- Li, J., Wang, L., Hu, J. & Xu, G. 2015. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis. *Nutrition, Metabolism and Cardiovascular Diseases*. 25(8):706–713.
- Liabeuf, S., Scaltieux, L.-M., Masmoudi, K., Roussel, B., Moragny, J., ... Gras-Champel, V. 2015. Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists: *Medicine*. 94(52):e2366.
- Limdi, N.A., Nolin, T.D., Booth, S.L., Centi, A., Marques, M.B., ... Beasley, T.M. 2015. Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio–Related Hemorrhage in Warfarin Users: A Prospective Cohort Study. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 65(5):701–709.
- Linkins, L.-A., Choi, P.T. & Douketis, J.D. 2003. Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous

Thromboembolism: A Meta-Analysis. *Annals of Internal Medicine*. 139(11):893.

MacDougall, C. 2017a. Penicillins, Cephalosporins, and Other  $\beta$ -Lactam Antibiotics. In: *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. McGraw-Hill Education.

MacDougall, C. 2017b. Aminoglycosides. In: *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. McGraw-Hill Education.

MacDougall, C. 2017c. Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents. In: *Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition*. McGraw-Hill Education.

Maina, M.W., Pastakia, S.D., Manji, I., Kirui, N., Kirwa, C. & Karwa, R. 2013. Describing the Profile of Patients on Concurrent Rifampin and Warfarin Therapy in Western Kenya: A Case Series. *Drugs in R&D*. 13(3):191–197.

Mak, M., Lam, C., Pineda, S.J., Lou, M., Xu, L.Y., ... Mitani, G. 2019. Pharmacogenetics of Warfarin in a Diverse Patient Population. *Journal of Cardiovascular Pharmacology and Therapeutics*. 24(6):521–533.

Manikandan, P. & Nagini, S. 2018. Cytochrome P450 Structure, Function and Clinical Significance: A Review. *Current Drug Targets*. 19(1).

Martín-Pérez, M., Gaist, D., de Abajo, F. & Rodríguez, L. 2018. Population Impact of Drug Interactions with Warfarin: A Real-World Data Approach. *Thrombosis and Haemostasis*. 118(03):461–470.

Martins, M.A.P., Reis, A.M.M., Sales, M.F., Nobre, V., Ribeiro, D.D., ... Ribeiro, A.L.P. 2013. Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. *BMC pharmacology & toxicology*. 14:27.

Mergenhagen, K.A., Olbrych, P.M., Mattappallil, A., Krajewski, M.P. & Ott, M.C. 2013. Effect of Azithromycin on Anticoagulation-Related Outcomes in Geriatric Patients Receiving Warfarin. *Clinical Therapeutics*. 35(4):425–430.

Moura, C.S., Acurcio, F.A. & Belo, N.O. 2009. Drug-Drug Interactions Associated with Length of Stay and Cost of Hospitalization. *Journal of Pharmacy & Pharmaceutical Sciences*. 12(3):266.

Mutalik, M. 2014. Review of Drug Interactions: A Comprehensive Update. *British Journal of Pharmaceutical Research*. 4(8):954–980.



- Nathisuwan, S., Dilokthornsakul, P., Chaikyapapruk, N., Morarai, T., Yodting, T. & Piriyanachanasorn, N. 2011. Assessing Evidence of Interaction Between Smoking and Warfarin. *Chest*. 139(5):1130–1139.
- Nelson, W.W., Desai, S., Damaraju, C.V., Lu, L., Fields, L.E., ... Schein, J.R. 2015. International Normalized Ratio Stability in Warfarin-Experienced Patients with Nonvalvular Atrial Fibrillation. *American Journal of Cardiovascular Drugs*. 15(3):205–211.
- Nieto, J.A., Solano, R., Ruiz-Ribó, M.D., Ruiz-Gimenez, N., Prandoni, P., ... Monreal, M. 2010. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. *Journal of Thrombosis and Haemostasis*. 8(6):1216–1222.
- Ningrum, V.D.A., Sufiyah, S., Dyah Widyastuti, I., Sufriyanto Yusuf, B. & Dullah, W. 2020. Bleeding Incidence in Patients Administered with Warfarin at Secondary Hospitals in Yogyakarta Province. *Indonesian Journal of Pharmacy*. (September, 30):217.
- Olesen, J.B., Lip, G.Y.H., Hansen, P.R., Lindhardsen, J., Ahlehoff, O., ... Torp-Pedersen, C. 2011. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. *Journal of Thrombosis and Haemostasis*. 9(8):1460–1467.
- Olinic, D.-M., Stanek, A., Tătaru, D.-A., Homorodean, C. & Olinic, M. 2019. Acute Limb Ischemia: An Update on Diagnosis and Management. *Journal of Clinical Medicine*. 8(8).
- Ozturk, M., Ipekci, A., Kiyak, S.K., Akdeniz, Y.S., Aydin, Y., ... Sogut, O. 2019. Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department. *Journal of Clinical Medicine Research*. 11(2):106–113.
- Palleria, C., Di Paolo, A., Giofrè, C., Caglioti, C., Leuzzi, G., ... Gallelli, L. 2013. Pharmacokinetic drug-drug interaction and their implication in clinical management. *Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences*. 18(7):601–610.
- Parikh, A.M., Spencer, F.A., Lessard, D., Emery, C., Baylin, A., ... Goldberg, R.J. 2011. Venous Thromboembolism in Patients With Reduced Estimated GFR: A Population-Based Perspective. *American journal of kidney diseases: the official journal of the National Kidney Foundation*. 58(5):746–755.

- Patel, R.J., Witt, D.M., Saseen, J.J., Tillman, D.J. & Wilkinson, D.S. 2000. Randomized, Placebo-Controlled Trial of Oral Phytonadione for Excessive Anticoagulation. *Pharmacotherapy*. 20(10):1159–1166.
- Patel, S., Singh, R., Preuss, C.V. & Patel, N. 2020. Warfarin. In: *StatPearls. Treasure Island (FL): StatPearls Publishing*. <http://www.ncbi.nlm.nih.gov/books/NBK470313/> Date of access: 14 Mar. 2020.
- Pavord, S. & Myers, B. 2011. Bleeding and thrombotic complications of kidney disease. *Blood Reviews*. 25(6):271–278.
- Pengo, V., Legnani, C., Noventa, F., Palareti, G., & the ISCOAT. 2001. Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding: A Multicenter Inception Cohort Study. *Thrombosis and Haemostasis*. 85(03):418–422.
- Pourhoseingholi, M.A., Baghestani, A.R. & Vahedi, M. 2012. How to control confounding effects by statistical analysis. *Gastroenterology and Hepatology From Bed to Bench*. 5(2):79–83.
- Pushpakom, S.P., Gambhir, N., Latif, A., Hadfield, K.D., Campbell, S. & Newman, W.G. 2011. Exacerbation of Hereditary Warfarin Resistance by Azathioprine. *Clinical and Applied Thrombosis/Hemostasis*. 17(3):293–296.
- Rice, P.J., Perry, R.J., Afzal, Z. & Stockley, I.H. 2003. Antibacterial prescribing and warfarin: a review. *British Dental Journal*. 194(8):411–415.
- Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J.M. & Briët, E. 1993. A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy. *Thrombosis and Haemostasis*. 69(03):236–239.
- Roth, J.A., Bradley, K., Thummel, K.E., Veenstra, D.L. & Boudreau, D. 2015. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. *Pharmacoepidemiology and drug safety*. 24(6):619–627.
- Rothberg, M.B., Celestin, C., Fiore, L.D., Lawler, E. & Cook, J.R. 2005. Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit. *Annals of Internal Medicine*. 143(4):241–250.
- Saum, L.M. & Balmat, R.P. 2016. Ceftriaxone Potentiates Warfarin Activity Greater Than Other Antibiotics in the Treatment of Urinary Tract Infections. *Journal of Pharmacy Practice*. 29(2):121–124.

- Schalekamp, T. 2008. Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins. *Archives of Internal Medicine*. 168(2):180.
- Schelleman, H., Bilker, W.B., Brensinger, C.M., Han, X., Kimmel, S.E. & Hennessy, S. 2008. Warfarin - Fluoroquinolones, Sulfonamides, or Azole Antifungals Interactions and the Risk of Hospitalization for Gastrointestinal Bleeding. *Clinical pharmacology and therapeutics*. 84(5):581–588.
- Schelleman, H., Brensinger, C.M., Bilker, W.B. & Hennessy, S. 2011. Antidepressant-Warfarin Interaction and Associated Gastrointestinal Bleeding Risk in a Case-Control Study. *PLoS ONE*. 6(6).
- Schulman, S. & Kearon, C. 2005. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *Journal of Thrombosis and Haemostasis*. 3(4):692–694.
- Schulman, S., Beyth, R.J., Kearon, C. & Levine, M.N. 2008. Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment. *Chest*. 133(6):257S-298S.
- Schulman, S., Melnyshyn, A., Ennis, D. & Rudd-Scott, L. 2010. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range. *Thrombosis Research*. 125(5):393–397.
- Shen, C., Huang, X., Li, J., Zhang, P., Li, L., ... Tang, H. 2016. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. *Xenobiotica*. 46(6):530–541.
- Shendre, A., Parmar, G.M., Dillon, C., Beasley, T.M. & Limdi, N.A. 2018. Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. *Pharmacotherapy*. 38(6):588–596.
- Shoeb, M. & Fang, M.C. 2013. Assessing Bleeding Risk in Patients Taking Anticoagulants. *Journal of thrombosis and thrombolysis*. 35(3):312–319.
- Suriapranata, I.M., Tjong, W.Y., Wang, T., Utama, A., Raharjo, S.B., ... Tai, S.S. 2011. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. *BMC Medical Genetics*. 12:80.
- Suzuki, S., Yamashita, T., Kato, T., Fujino, T., Sagara, K., ... Fu, L.-T. 2007. Incidence of Major Bleeding Complication of Warfarin Therapy in Japanese Patients With Atrial Fibrillation. *Circulation Journal*. 71(5):761–765.
- Teklay, G., Shiferaw, N., Legesse, B. & Bekele, M. 2014. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. *Thrombosis Journal*. 12(1):20.

- The GUSTO Investigator. 1993. An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. *New England Journal of Medicine*. 329(10):673–682.
- Tie, J.-K. & Stafford, D.W. 2017. Functional Study of the Vitamin K Cycle Enzymes in Live Cells. *Methods in enzymology*. 584:349–394.
- Vazquez, S.R., Rondina, M.T. & Pendleton, R.C. 2008. Azathioprine-Induced Warfarin Resistance. *The Annals of pharmacotherapy*. 42(7):1118–1123.
- Vecsler, M., Loebstein, R., Almog, S., Kurnik, D., Goldman, B., ... Gak, E. 2006. Combined genetic profiles of components and regulators of the vitamin K-dependent  $\gamma$ -carboxylation system affect individual sensitivity to warfarin. *Thrombosis and Haemostasis*. 95(02):205–211.
- Violi, F., Lip, G.Y., Pignatelli, P. & Pastori, D. 2016. Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True? *Medicine*. 95(10).
- Wadelius, M., Chen, L.Y., Downes, K., Ghorri, J., Hunt, S., ... Deloukas, P. 2005. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. *The Pharmacogenomics Journal*. 5(4):262–270.
- Wadelius, M., Chen, L.Y., Lindh, J.D., Eriksson, N., Ghorri, M.J.R., ... Deloukas, P. 2009. The largest prospective warfarin-treated cohort supports genetic forecasting. *Blood*. 113(4):784–792.
- Wakkee, M., Hollestein, L.M. & Nijsten, T. 2014. Multivariable Analysis. *Journal of Investigative Dermatology*. 134(5):1–5.
- Westphal, J.F. 2000. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin: Macrolide-induced metabolic drug interactions. *British Journal of Clinical Pharmacology*. 50(4):285–295.
- Wysowski, D.K., Nourjah, P. & Swartz, L. 2007. Bleeding Complications With Warfarin Use: A Prevalent Adverse Effect Resulting in Regulatory Action. *Archives of Internal Medicine*. 167(13):1414.
- Zaman, J.A.B. & Bhandari, A.K. 2019. Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease: *Journal of Cardiovascular Pharmacology and Therapeutics*. (July, 8).
- Zanger, U.M. & Schwab, M. 2013. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacology & Therapeutics*. 138(1):103–141.



- Zehnder, J.L. 2017. Drugs Used in Disorders of Coagulation. In: *Basic and Clinical Pharmacology 14th Edition*. McGraw Hill Professional. pp. 1264.
- Zhang, K., Young, C. & Berger, J. 2006. Administrative Claims Analysis of the Relationship Between Warfarin Use and Risk of Hemorrhage Including Drug-Drug and Drug-Disease Interactions. *Journal of Managed Care Pharmacy*. 12(8):640–648.